MaaT Pharma reports positive Phase III results for MaaT013, its microbiome-based therapy for gastrointestinal GvHD, achieving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback